Changing Supplier Controls Requirements

Instructor: John E Lincoln
Product ID: 702277
  • Duration: 90 Min

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556


Read Frequently Asked Questions

This training on FDA supplier controls will help you refine your supplier chain management and vendor audits to match the FDA's tougher position. We will evaluate the chief areas of change to see how to better prepare a supplier chain management and audit program.

Why Should You Attend:

Recent FDA statements and actions indicate the past ways of managing a company's supply chain / outsourcing will no longer be acceptable. Increasingly reports from the field indicate that the agency is using high-profile cases to drive compliance to smaller companies and suppliers. CGMP compliance cannot be passed on to suppliers; however suppliers must meet specific CGMP requirements. Proof for better science is also a new expectation. "Business as usual" is never acceptable. Don't be caught off guard by these major shifts in emphasis.

This presentation will help you refine supplier management and audits to match the FDA's tougher position. We will evaluate the chief areas of change to see how to better prepare a supplier chain management and audit program. This webinar will provide valuable assistance to all regulated companies in evaluating their existing supply chain control / compliance and vendor audits in light of the changes in the FDA's CGMP supplier management paradigm. Once potential problem areas are identified, a company can evaluate / perform a gap analysis, and then put in place the necessary fixes to ensure continuing compliance.

Areas Covered in the Webinar:

  • The Globalization of the Supply Chain and What That Means
  • Avoid Complacency from Past Good FDA / ISO audits
  • Supplier Ranking Models
  • Mandated Supplier Controls; Change Controls
  • COAs / COCs
  • The Tiered Risk-Based Audit Approach
  • Entropy; Maintain the Edge/State of Control

Who Will Benefit:

The following personnel from the medical device, diagnostic, pharmaceutical, neutraceutical and biologics fields will benefit:

  • Senior management
  • Regulatory affairs
  • Quality assurance
  • Purchasing
  • Production
  • Engineering
  • All personnel involved in a U.S. FDA-regulated environment, especially those involved in the establishment, monitoring, and review / audits of outsourced parts and services used in regulated medical products

Instructor Profile:

John E. Lincoln is principal of J. E. Lincoln and Associates LLC, a consulting company with over 31 years’ experience in U.S. FDA-regulated industries, and 17 years as a full-time consultant. Mr. Lincoln has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, design control / design history files, and technical files. He's held positions in manufacturing engineering, QA, QAE, regulatory affairs, to the level of director and VP (R&D). In addition, Mr. Lincoln has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. Mr. Lincoln is a graduate of UCLA.

Topic Background:

There has been a major shift in the emphasis of U.S. FDA requirements for supplier CGMP compliance. The FDA has implemented major global initiatives. Companies are required to tightly manage their entire supply chain. The infrastructure behind the COA / COC is being challenged. Such changes in focus has a major impact on individual compliance objectives, efforts and measurements of success. The agency has come under increasing negative publicity due to major publicized product failures / recalls, leading to public concern over insufficient oversight of the entire medical product supply chain, including global outsourcing. Of both raw materials, components, as well as services. Better science requirement impacts suppliers as well. All this is affecting the agency's approach to audits and their expectations for companies. These areas of change will be evaluated to see how to better prepare address supplier chain management and vendor audits.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
21 CFR Part 11 Compliance for SaaS/Cloud Applications - 80202SEM

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed